Monday, 16 Sep 2019

You are here

We Measure What we do in RA, But so What?

We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change. At EULAR 2018 a study of 1776 patients from the VA database showed again the notion that if a patient is in high disease activity, treatment changes are made only half the time (FRI0018). My response to this is that the measures are not reflecting active RA (i.e. scores driven by non-inflammatory pain, tender joints from OA), or the patient refuses to accept more treatment or the most likely is that the score is not being calculated (i.e. for billing reimbursement, the components are collected but scores are not calculated during the visit) as the physician doesn’t think the disease is active (enough) to warrant a treatment change. However, even more strangely, 15% who were in remission had dose increasing or a new drug started and 21 to 25% in low disease activity had increases in treatment. I can say that the disease activity instruments used in the study (DAS28, CDAI and RAPID3) had a ‘dose response’ meaning that the frequency of treatment increases was lowest in remission, and highest in high disease activity and there will never be 100% concordance with outcome measures and treatment changes in clinical practice. It is too bad we don’t have the HbA1C (glycated Hbg) equivalent of RA – one easy test reflecting recent disease activity that we could target.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.

74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs. A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).